Home›Mavorixafor›Mavorixafor + Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance

Does Mavorixafor Interact with Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance?

Mavorixafor and Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance have a contraindicated drug interaction according to U.S. FDA drug labeling data. Concomitant use is contraindicated. Mavorixafor inhibits CYP2D6, increasing substrate exposure and risk of adverse reactions. The mechanism involves inhibition of cyp2d6-mediated metabolism of substrates. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Contraindicated
Mavorixafor Class
CXC Chemokine Receptor 4 Antagonist
Management
Do not take together
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Mavorixafor and Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance occurs because inhibition of cyp2d6-mediated metabolism of substrates. Clinically, this means concomitant use is contraindicated. mavorixafor inhibits cyp2d6, increasing substrate exposure and risk of adverse reactions. Because of the severity of this interaction, these medications are contraindicated — meaning they should not be taken together under any circumstances. If you are currently taking both, contact your healthcare provider immediately to discuss alternatives.

What To Tell Your Doctor or Pharmacist

If you are taking Mavorixafor and your doctor is considering prescribing Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask about alternative medications that do not interact with your current regimen
  • Ask how frequently you should be monitored while these are co-prescribed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Mavorixafor(Xolremdi)+💊 Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance

Severity & Interaction Details

⛔
contraindicated
Avoid this combination
FDA labeling lists this pair as contraindicated. The risk outweighs the benefit in nearly all cases.
Severity scale
MinorContra
On record
Yes
Drug A class
CXC Chemokine Receptor 4 Antagonist
Drug B class
—
Source
NLP:mavorixafor

What this means in plain English

Concomitant use is contraindicated. Mavorixafor inhibits CYP2D6, increasing substrate exposure and risk of adverse reactions.

What the FDA label says

"Inhibition of CYP2D6-mediated metabolism of substrates"

📖 Source: NLP:mavorixafor

Share this result:

WhatsAppText / SMSEmail
Also share on:XFacebook
Add more drugs
Check Mavorixafor and Cyp2d6 Substrates Highly Dependent On Cyp2d6 For Clearance against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.